
Sells Monster energy drinks, distributed mostly by Coca-Cola bottlers.
Monster Beverage at a glance: how it scores on value, growth, quality, health, shareholder returns and trend. The fuller the shape, the stronger the company. Behind each axis are six pass-or-fail checks from its filings, spelled out in the chapters below. Point at an axis to see them.
A mixed picture - strengths and real weaknesses - 23 of 36 checks passed.
What you pay today for what the business produces, measured against MNST's own history and its peers, never a universal rule.
Fairly priced on some measures, rich on others - earnings multiple above its own long-run norm.
→At 20.3x earnings, the market is paying +14% more than MNST's own 11-year median of 17.8x. Expectations are elevated, so more has to go right to justify the price.
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→At 20.3x earnings, the market is paying +14% more than MNST's own 11-year median of 17.8x. Expectations are elevated, so more has to go right to justify the price.
4.9%FCF yield today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→At 4.9%, you get less cash per dollar of market value than the 11-year median of 6.1% - the market is charging more for the same cash.
Value asks what you pay for each dollar of earnings, sales or cash the business produces. A high multiple isn't automatically bad - fast growers earn theirs - but a price far above the company's own history means the market expects a lot to go right. We compare each multiple to the company's own past and to its sector, never to a universal rule.
| – | Cheaper than its own history (earnings) | no multiple history |
| ✓ | Earnings yield beats a long bond (4%) | 4.9% vs 4.0% |
| – | Better cash yield than its own history | under 3 years of cash-flow history |
| ✓ | Free cash flow yield above 3% | 4.9% vs 3.0% |
| – | Cheap on enterprise value | EBITDA unavailable |
| ✓ | Price isn't outrunning growth | PEG 1.01 |
What the company has actually reported - is it selling more, and is more of it becoming profit?
The business is genuinely growing - revenue +20.4% in the last year, and it's consistent.
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Revenue reached $8.3B in 2025, compounding +10% a year since 2022 though the pace has cooled. The trailing twelve months are already running at $9.2B, ahead of the last full year.
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Net income was $1.9B in 2025, compounding +17% a year over three years. Earnings per share moved +35% over the last twelve months. Trailing twelve-month profit stands at $2.1B.
+11%revenue growth, FY 2025
→In 2025 revenue grew +11% while earnings moved +26% - when the earnings line runs above revenue, each new dollar of sales is arriving more profitably.
Growth here is what the company has actually reported to the SEC - not a forecast. We look at the last year, the three-year pace, whether growth is speeding up or slowing down, and whether it's been consistent rather than one lucky year. Hatched bars are fourth quarters we derived from annual filings (companies file a full-year 10-K rather than a Q4 report).
| ✓ | Outgrew its sector last year | 20.4% vs 3.6% (sector 70th pct, n=55) |
| ✓ | Sustained growth beats its sector (3 years) | 9.5% vs 8.3% (sector 70th pct, n=52) |
| ✓ | Profits grew last year | 35.2% vs 0.0% |
| ✕ | Profit growth beats its peers | 20.1% vs 30.1% (sector 70th pct, n=40) |
| ✓ | Growth is speeding up, not slowing | 1y 20.4% vs 3y 9.5% |
| ✓ | Grew per share, not just in total | 42.4% vs 0.0% |
Whether the growth makes real money - margins, returns on capital, and whether profits turn into cash.
Rare profitability: margins and returns on capital are well above its peers.
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→Operating margin widened 4 points to 29% since 2022. After everything, 23 cents of each sales dollar reaches net profit.
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→Operating cash flow tracks reported profit almost exactly (105%). The earnings are real cash, not accounting.
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→ROE 23% and ROCE 28% sit close together - the returns come from the business itself, not from borrowing.
→Of $8.3B in sales, $4.6B survives production costs, $2.4B survives running the company, and $1.9B - 23¢ of every dollar - reaches the bottom line.
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→24 cents of every sales dollar became free cash in 2025, up 13 points since 2022.
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→The biggest claim on each sales dollar is capital spending, at 2% of revenue (stock compensation 2%). That share has fallen since 2022, so the cost of competing is easing.
→Operating profit outgrew revenue in only 2 of the last 5 years. Costs are growing roughly in step with the business, so scale isn't yet paying for itself.
→MNST earns 28.3% on the capital it employs, well above the 10% most investors treat as the cost of capital. It was 21.7% in 2022, so the trend is up, and the pace is picking up.
Quality asks whether the growth makes real money. Margins show how much of each sale survives costs; return on equity shows what shareholders earn on their capital; and the profit-to-cash comparison catches companies whose accounting profits never turn into actual cash.
| ✓ | Better gross margins than peers | 55.5% vs 39.1% (sector 70th pct, n=52) |
| ✓ | Runs leaner than peers (operating margin) | 29.2% vs 11.9% (sector 70th pct, n=53) |
| ✓ | Actually profitable | TTM net income $2.1B |
| ✓ | Earns well on shareholders' money | 22.7% vs 17.0% (sector 70th pct, n=51) |
| ✓ | Earns a real return on the capital it employs | 27.8% vs 10.0% |
| ✓ | Profits are cash, not accounting | 1.05 vs 0.80 |
The balance sheet stress test: could MNST survive a bad year?
Financially sound overall, with one or two things worth watching.
◌ 2026 = the latest balance sheet (2026-06-30), not a fiscal year-end
→Debt isn't clearly tagged in MNST's filings, so treat the balance sheet with extra care rather than assuming zero.
→The company's own capital grew from $8.2B in 2023 to $9.4B (+14%). The business is building book value rather than consuming it.
Health asks one question: can the business survive a bad year? We check whether near-term bills are covered, whether debt is modest and shrinking, whether earnings comfortably pay the interest, and - for loss-makers - how many years of cash are left at the current burn rate.
| ✓ | Comfortable near-term liquidity | 3.73 vs 1.50 |
| – | Debt isn't dominating | debt unreported - cannot verify |
| – | Debt trending the right way | under 5 years of balance-sheet history |
| – | Earnings cover the interest | operating income or interest expense unavailable |
| ✓ | Converts sales to cash better than its sector | 24.3% vs 13.9% (sector 70th pct, n=56) |
| ✓ | Self-funding | TTM free cash flow $2.1B |
How much cash actually flows back to owners - dividends, buybacks, whether the share count truly falls, and whether what is handed back is affordable.
Cash comes back to owners, with a caveat or two in the checks below.
→Stock compensation ($126M) outweighs the $104M returned - the dilution is winning.
→The count shrank 2.8% last year - buybacks are outrunning stock compensation.
Both lines start at 100 in 2011, so the gap between them is what each share gained or lost. Share counts are split-adjusted.
→MNST has shrunk its share count -12% from 2011 to 2025, so each remaining share owns more of the business. Revenue per share is +454% over the same years.
A company can trumpet billions in buybacks while quietly issuing nearly as much stock to employees. What matters to you is the net effect: is the share count actually falling? If not, the 'return' is mostly recycling.
| ✓ | Share count isn't climbing | shares down 7.7% over 3 years |
| ✓ | Buybacks outpace the stock issued to staff | $221M bought back vs $136M of stock compensation |
| ✓ | What it hands back fits inside its cash flow | 10.5% vs 100.0% |
| ✕ | Meaningful yield to owners (dividends and buybacks) | $221M returned, 0.5% of market value |
| ✕ | Buybacks are sustained, not one-off | $221M bought back in the last twelve months, 0.00 the year before; no dividend |
| ✕ | Buybacks growing | $221M vs 0.00 the year before; no dividend |
What the market is doing about all of the above. This is price behaviour, not a fact about the business - read it as the market's current opinion, scored on six checks like every other chapter. The market is the S&P 500, measured by the SPY ETF with dividends included, over 3 months (63 trading sessions) and 12 months (252).
Mixed signals from the market - some trends up, some rolling over.
Chart by TradingView
→MNST is in a downtrend. The price is below the band where recent trading settled and that band is still falling, so nothing in the picture has turned yet. Both the last two weeks and the month-ago comparison point down as well, so nothing here disagrees with the downtrend. The band drawn for the coming weeks turns downward partway through, so that support is set to thin out from there.
The trend read comes from the daily Ichimoku picture, a standard trend indicator, translated out of its jargon. It builds a band from the midpoints of the last 9, 26 and 52 sessions' highs and lows - in effect, the range where recent trading has settled - and draws that band 26 sessions into the future. Price above the band is an uptrend, below it a downtrend, inside it no trend. Because the band is drawn forward, the support for the next few weeks is already fixed and a change of its direction can be seen coming. We also compare the last two weeks against the last month, and today's price against where it stood a month ago. None of this says anything about the business; it describes the price only, and it is not advice. Where a check says 'the S&P 500', the comparison is with the SPY ETF including dividends, on the same adjusted basis as the stock's own price: short means 3 months, 63 trading sessions; long means 12 months, 252.
| ✕ | Trading above its cloud | 0.00 vs 0.50 |
| ✓ | Long-term trend structure is healthy | 47.39 vs 41.78 |
| ✕ | Rising over 3 months | -2.1% vs 0.0% |
| ✕ | Beating the S&P 500 over 3 months | -2.1% vs 4.7% |
| ✓ | Beating the S&P 500 over 12 months | 38.1% vs 20.0% |
| ✓ | Not in a deep hole | -12.3% from its 52-week high |
What the people running the company do with their own shares - reported to the SEC within two days, classified so pay-plumbing doesn't masquerade as conviction.
→No open-market buying, and $16M of selling across 5 months. Selling alone is a weak signal - much of it is pre-scheduled - but the absence of buying tells you no insider saw the price as a bargain.
| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-10 | Guy Carling | CEO, EMEA and OSP | SELL | 19,000 | $2M |
| 2026-05-14 | Mark J Hall | Director | exercise | 12,000 | $533,640 |
| 2026-05-14 | Mark J Hall | Director | exercise | 15,000 | $549,300 |
| 2026-05-14 | Mark J Hall | Director | exercise | 12,000 | $609,840 |
| 2026-05-14 | Mark J Hall | Director | exercise | 15,000 | $904,500 |
| 2026-05-14 | Mark J Hall | Director | SELL | 54,000 | $5M |
| 2026-05-14 | Emelie Tirre | Chief Strategy Officer | SELL | 10,000 | $857,400 |
| 2026-05-14 | Emelie Tirre | Chief Strategy Officer | exercise | 2,248 | $99,969 |
| 2026-05-13 | Thomas J Kelly | Chief Financial Officer | SELL | 7,000 | $614,670 |
| 2026-05-13 | Emelie Tirre | Chief Strategy Officer | exercise | 17,752 | $789,431 |
Most insider filings are not trades: stock grants, option exercises and tax withholding are how executives get paid, and gifts are estate planning. The signal lives in open-market transactions - a buy means an insider chose to spend their own cash on the stock. Sells are murkier: many are pre-scheduled 10b5-1 plans set months in advance. That's why the chart counts only open-market activity, and the table labels every row.